Mutation identification and prediction for severe cardiomyopathy in Alström syndrome, and review of the literature for cardiomyopathy

Table 2 Clinical features in patients with Alström syndrome

Patient No	Weight (kg)	Obesity	Vision Loss	Hearing loss	Homa-IR	Hyperlipidemia (mg/dL)	Treatment	Other	EF % 1	EF % 2
A	62	+	+	+	12.7	+	Enalapril Furosemid	Acanthosis Nigrikans, nephrocalcinosis	40	41	Ex 19 y
B	64	+	+	+			Enalapril Furosemid Spironolakton	Scoliosis	26	48
C	17	+	+	−			Kaptopril Furosemid Digoxin		42	43	43
D	18	+	+	−	1.58	−	Captopril		59	55
E	6	−	+	−			Enalapril Furosemid Spironolakton Digoksin Aspirin Metacartin		43	39	Ex in infancy
F	7	+	+	−			Digoxin Captopril Furosemid Spironolakton		25	35	Ex infancy
G	79	+	+	+			Enapril		59	58	Ex 17 y
H	72	+	+	+			Enapril		45	55
J	11	−	+	−			Levosimendan Kaptopril, Spironolakton		40	29

ISSN: 1750-1172